T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
JPMorgan Chase
JPM
|
+$1.7B |
| 2 |
Verizon
VZ
|
+$1.36B |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$1.31B |
| 4 |
US Bancorp
USB
|
+$1.29B |
| 5 |
Merck
MRK
|
+$1.23B |
Top Sells
| 1 |
Amazon
AMZN
|
+$5.38B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$4.57B |
| 3 |
Tesla
TSLA
|
+$3.67B |
| 4 |
TMX
Terminix Global Holdings, Inc.
TMX
|
+$3.44B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.43B |
Sector Composition
| 1 | Technology | 26.72% |
| 2 | Healthcare | 19.64% |
| 3 | Financials | 12.69% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Communication Services | 7.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2051
Arrow Financial
AROW
$478M
| $586K | ﹤0.01% |
17,818
+3,070
| +21% | +$101K |
|
2052
Recursion Pharmaceuticals
RXRX
$2.11B
| $585K | ﹤0.01% |
75,919
+39,713
| +110% | +$306K |
|
|
EVOP
2053
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
| $584K | ﹤0.01% |
17,250
+631
| +4% | +$21.4K |
|
2054
Nektar Therapeutics
NKTR
$926M
| $583K | ﹤0.01% |
17,192
-250
| -1% | -$8.48K |
|
2055
Protolabs
PRLB
$1.18B
| $583K | ﹤0.01% |
22,830
+5,604
| +33% | +$143K |
|
2056
Dillards
DDS
$8.97B
| $581K | ﹤0.01% |
1,799
-157
| -8% | -$50.7K |
|
|
SP
2057
DELISTED
SP Plus Corporation
SP
| $581K | ﹤0.01% |
16,736
-260
| -2% | -$9.03K |
|
2058
EchoStar
SATS
$21.5B
| $580K | ﹤0.01% |
34,778
+14
| +0% | +$233 |
|
|
ATSG
2059
DELISTED
Air Transport Services Group, Inc.
ATSG
| $580K | ﹤0.01% |
22,326
+1,514
| +7% | +$39.3K |
|
2060
Vicor
VICR
$2.28B
| $580K | ﹤0.01% |
10,787
+978
| +10% | +$52.6K |
|
2061
Amylyx Pharmaceuticals
AMLX
$1.24B
| $579K | ﹤0.01% |
+15,683
| New | +$579K |
|
2062
Ingles Markets
IMKTA
$1.32B
| $578K | ﹤0.01% |
5,987
+186
| +3% | +$18K |
|
2063
Sonic Automotive
SAH
$2.73B
| $578K | ﹤0.01% |
11,728
-3,045
| -21% | -$150K |
|
2064
Cushman & Wakefield
CWK
$3.85B
| $577K | ﹤0.01% |
46,278
+2,215
| +5% | +$27.6K |
|
|
HPP
2065
Hudson Pacific Properties
HPP
$1.11B
| $575K | ﹤0.01% |
59,054
+1,921
| +3% | +$18.7K |
|
2066
Myriad Genetics
MYGN
$674M
| $574K | ﹤0.01% |
39,571
+1,077
| +3% | +$15.6K |
|
2067
Astec Industries
ASTE
$1.06B
| $573K | ﹤0.01% |
14,088
+355
| +3% | +$14.4K |
|
|
ADAM
2068
Adamas Trust, Inc. Common Stock
ADAM
$644M
| $572K | ﹤0.01% |
55,838
+1,281
| +2% | +$13.1K |
|
2069
Ligand Pharmaceuticals
LGND
$3.23B
| $568K | ﹤0.01% |
8,496
-4,772
| -36% | -$319K |
|
|
RC
2070
Ready Capital
RC
$689M
| $567K | ﹤0.01% |
50,865
+1,514
| +3% | +$16.9K |
|
2071
XPEL
XPEL
$960M
| $564K | ﹤0.01% |
9,389
-88
| -0.9% | -$5.29K |
|
|
PGRE
2072
Paramount Group
PGRE
$1.57B
| $563K | ﹤0.01% |
94,714
+2,171
| +2% | +$12.9K |
|
|
HAYN
2073
DELISTED
Haynes International, Inc.
HAYN
| $563K | ﹤0.01% |
12,323
-289
| -2% | -$13.2K |
|
2074
Ennis
EBF
$463M
| $561K | ﹤0.01% |
25,305
+8,312
| +49% | +$184K |
|
2075
Vericel Corp
VCEL
$1.62B
| $559K | ﹤0.01% |
21,239
+596
| +3% | +$15.7K |
|